In addition, a large number of clinical studies have shown that GLP-/GIP dual agonists can reduce LFC, VAT, and body weight, and have an improvement effect on both NAFLD and NASH [131,132]
However, more powerful weight loss does not automatically mean treatment is right for every patient
The Verification Perspective The compounded GLP-1 telehealth space has been under increased regulatory scrutiny in recent years
When we are on a diet, reducing our caloric intake, or when we just don't have our regular appetite...or if semaglutide is making us nauseous...our protein intake suffers
By starting with small, gradual doses, this approach aims to promote benefits like improved energy, cognitive function, and metabolic balancewhile minimizing potential side effects
95% CI, 0.35 to 3.14)